hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

Inclusion Criteria:

• Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg/m2,including boundary value;

• The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society ofhepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and theliver function grade was child-pugh B or child-pugh C, with a score range of 7-12points, and Model for End-Stage Liver Disease score≤21 points.

• Have not received stem cell therapy in the recent 6 months;

• Subjects will be able to sign the informed consent in accordance with the studyprocedures and instructions.

Exclusion Criteria:

• Insufficiency of vital organs, such as heart, kidney and lung;

• End-stage cirrhosis with severe complications, including but not limited to: hepaticencephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites,etc.

• Concomitant peritonitis, pneumonia, or other types of infection not under control;

• Have a history of severe allergic reaction or allergy to two or more kinds of foodor medicine;

• Positive serum HIV antibody and syphilis antibody;

• Alpha fetoprotein>400ng/mL with primary liver cancer or without imaging evidence;

• Chronic liver disease and cirrhosis are caused by non-chronic hepatitis B virusinfection, or other factors except chronic hepatitis B virus infection ;

• Patients with severe mental illness and cognitive impairment;